Clinical Trials · NCT06779929
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 70,000
- Start date
- Nov 2024
- Locations
- 1 site, United States
- Primary endpoint
- Composite CV outcome